# Bristol-Myers Squibb Company (BMY) — Q3-2017 Earnings Results

**Report date:** 2017-10-26 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q3-2017

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Misses on EPS — Stock Down 4.77%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.75 | N/A | -3.49% |

### Management Commentary

**Tone:** Defensive

Management expressed concerns about market conditions impacting performance. They emphasized their ongoing commitment to their product pipeline.

**Key quotes:**

> We are focused on maintaining our current pipeline and addressing market challenges.

> Our commitment to innovation remains strong despite current pressures.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Bristol Myers Squibb's earnings report showed a slight miss on EPS, which contributed to a significant drop in stock price. Investors may be concerned about the company's ability to navigate current market challenges and the lack of guidance could add to uncertainty. The stock's decline reflects these worries as the company looks to stabilize its performance moving forward.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q3-2017_